AMPLATZER TALISMAN
Device
Abbott Laboratories
Total Payments
$3.3M
Transactions
3,702
Doctors
1,286
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.1M | 1,387 | 651 |
| 2023 | $1.3M | 1,732 | 746 |
| 2022 | $983,678 | 583 | 26 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.7M | 1,355 | 82.4% |
| Consulting Fee | $219,910 | 89 | 6.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $206,541 | 112 | 6.2% |
| Food and Beverage | $97,607 | 1,900 | 2.9% |
| Travel and Lodging | $52,067 | 239 | 1.6% |
| Compensation for serving as faculty or as a speaker for a medical education program | $5,600 | 1 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $3,120 | 5 | 0.1% |
| Debt forgiveness | $1,000 | 1 | 0.0% |
Payments by Type
Research
$2.7M
1,355 transactions
General
$585,846
2,347 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| AMPLATZER PFO Occluder Post Approval Study (PFO PAS) | Abbott Laboratories | $1.6M | 0 |
| AMPLATZER PFO Occluder Post Approval Study | Abbott Laboratories | $1.2M | 0 |
| OSB Lead-AMPLATZERPFOOccluder New EnrollmentPAS | Abbott Laboratories | $6,887 | 0 |
| Amplatzer PFO Occluder PAS | Abbott Laboratories | $760.00 | 0 |
| TRILUMINATE Study With Abbott Transcatheter Clip Repair System in Patients With Moderate or Greater TR (TRILUMINATE) | Abbott Laboratories | $150.00 | 0 |
| Cephea Early Feasibility Study | Abbott Laboratories | $130.00 | 0 |
Top Doctors Receiving Payments for AMPLATZER TALISMAN — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Cardiovascular Disease | Monterey, CA | $6,357 | 12 |
| , MD | Interventional Cardiology | Tallahassee, FL | $6,144 | 21 |
| , APNP | Registered Nurse | Milwaukee, WI | $5,949 | 4 |
| , M.D | Clinical Cardiac Electrophysiology | Phoenix, AZ | $5,852 | 3 |
| , M.D | Cardiovascular Disease | Washington, DC | $4,760 | 4 |
| , MD | Vascular Neurology | Los Angeles, CA | $4,750 | 5 |
| , M.D., M.P.H | Neurology | Houston, TX | $4,381 | 10 |
| , MD | Cardiovascular Disease | Kansas City, KS | $4,286 | 15 |
| , MD | Specialist | Minneapolis, MN | $3,757 | 10 |
| , M.D | Neurology | Philadelphia, PA | $3,616 | 7 |
| , MD | Cardiovascular Disease | Sacramento, CA | $3,510 | 4 |
| , M.D | Cardiovascular Disease | Newark, NJ | $3,500 | 2 |
| , M.D | Neurology | Greensboro, NC | $3,222 | 5 |
| , MD | Cardiovascular Disease | Pensacola, FL | $3,163 | 3 |
| , MD | Cardiovascular Disease | Minneapolis, MN | $3,100 | 4 |
| , M.D | Student in an Organized Health Care Education/Training Program | Philadelphia, PA | $3,000 | 1 |
| , M.D | Internal Medicine | Houston, TX | $2,954 | 4 |
| , MD | Internal Medicine | Kyle, TX | $2,923 | 8 |
| Jasmina Katinic | Nurse Practitioner | St Petersburg, FL | $2,893 | 5 |
| , MD | Advanced Heart Failure and Transplant Cardiology | Falls Church, VA | $2,888 | 1 |
| , MD | Internal Medicine | Stanford, CA | $2,811 | 5 |
| , M.D | Pediatric Cardiology | Orlando, FL | $2,768 | 2 |
| , M.D | Interventional Cardiology | La Jolla, CA | $2,681 | 1 |
| , D.O | Internal Medicine | Lincoln, NE | $2,678 | 6 |
| , MD | Internal Medicine | La Jolla, CA | $2,500 | 1 |
Ad
Manufacturing Companies
- Abbott Laboratories $3.3M
Product Information
- Type Device
- Total Payments $3.3M
- Total Doctors 1,286
- Transactions 3,702
About AMPLATZER TALISMAN
AMPLATZER TALISMAN is a device associated with $3.3M in payments to 1,286 healthcare providers, recorded across 3,702 transactions in the CMS Open Payments database. The primary manufacturer is Abbott Laboratories.
Payment data is available from 2022 to 2024. In 2024, $1.1M was paid across 1,387 transactions to 651 doctors.
The most common payment nature for AMPLATZER TALISMAN is "Unspecified" ($2.7M, 82.4% of total).
AMPLATZER TALISMAN is associated with 6 research studies, including "AMPLATZER PFO Occluder Post Approval Study (PFO PAS)" ($1.6M).